| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Watton Corey Michael serves as a Director at ZVRA. Across recent SEC filings that breaks down to 5 buys and 0 sells. Those positions are worth an estimated $20K at current prices.
Historically, Watton Corey Michael's trades have earned a below-average insider score of 46/100 across 5 rated trades. Over a 12-month horizon, 40.0% of those trades were profitable, with an average 12-month return of +1.1%.
The biggest single holding is ZVRA (~$20K) as Director. Net of sales, the recent Form 4 record there shows accumulation of 1,800 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 28, 2025 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 300 | $7.84 | $2,351.52 | +20.0% | +18.2% | +16.7% | |
| Oct 11, 2024 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 500 | $7.92 | $3,957.65 | +50.0% | -0.6% | +34.9% | |
| Jun 23, 2023 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 275 | $5.95 | $1,635.67 | +37.9% | -9.8% | -21.2% | |
| Jun 9, 2023 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 325 | $5.52 | $1,794.00 | +81.3% | -4.5% | -15.8% | |
| May 30, 2023 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 400 | $5.11 | $2,042.12 | New | +1.0% | -9.2% |